NCT06811454

Brief Summary

The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
76

participants targeted

Target at P25-P50 for not_applicable depression

Timeline
32mo left

Started Aug 2026

Typical duration for not_applicable depression

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 31, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 6, 2025

Completed
1.5 years until next milestone

Study Start

First participant enrolled

August 3, 2026

Expected
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2028

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2029

Last Updated

January 23, 2026

Status Verified

January 1, 2026

Enrollment Period

1.7 years

First QC Date

January 31, 2025

Last Update Submit

January 22, 2026

Conditions

Keywords

Post treatment Depression

Outcome Measures

Primary Outcomes (4)

  • Feasibility as assessed by listening rate

    80% listening rate of daily audio content

    12 weeks

  • Feasibility as assessed by sample retention rate

    80% sample retention

    12 weeks

  • Acceptability rate as assessed by satisfaction rating of daily audio content

    (\>8 median satisfaction rating of daily audio content is measured as accepatble

    12 weeks

  • Acceptability rate as assessed by Client Satisfaction Questionnaire (CSQ-8) post-MINDSET

    \>24 on the Client Satisfaction Questionnaire (CSQ-8) post-MINDSET will be considered as acceptable. CSQ-8 is a list of questions rating the satisfaction ranging from quite dissatisfied to very satisfied

    12 weeks

Secondary Outcomes (2)

  • Symptoms of depression as measured by PROMIS-D-SF

    12 weeks

  • Symptoms of anxiety as measured by PROMIS-A-SF

    12 weeks

Study Arms (2)

ARM 1

EXPERIMENTAL

Participants will be randomized to MINDSET

Behavioral: MINDSET

ARM 2

OTHER

Participants will be randomized to EUC

Behavioral: Enhanced Usual Care (EUC)

Interventions

MINDSETBEHAVIORAL

Participants randomized to MINDSET will receive a text message at their preferred time each day for 8 weeks containing a link to the 15-minute audio content. At the end of each week (on day 7), participants will receive a second link to the weekly survey in the text. Participants will be able to play the audio content on their device by clicking the first link and access the weekly survey by clicking the second.

ARM 1

Participants will receive a 1-page brochure summarizing publicly available information on depression self-care strategies via text each week for 8 weeks on the same day they receive the text message containing a link to the weekly survey (day 7). This information will come from the Facing Forward: Life After Cancer Treatment booklet from the National Cancer Institute.38 Weekly topics will include: 1) Reducing stress; 2) Coping with stress; 3) Coping with depression; 4) Feeling angry; 5) Feeling alone; 6) Finding meaning after treatment; 7) Social relationships; and 8) Seeking support. These materials do not include any content on mindfulness or cognitive therapy.

ARM 2

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Self-reported mild to moderately-severe symptoms of depression (score 5-19 on PHQ-9).
  • A diagnosis of stage 0-III breast, prostate, or colorectal cancer.
  • Completion of primary cancer treatment within 2 years (excludes hormone therapy).
  • An ability to provide informed consent.
  • An ability to read and speak English.
  • Access to a web-enabled device (phone, tablet, computer).

You may not qualify if:

  • Self-reported minimal and severe depressive symptoms (\<4 and \> 20 on PHQ-9).
  • Self-reported suicidal ideation (\>1 on item 9 PHQ-9).
  • Another psychological, medical, or other condition/issue determined that necessitates priority treatment and/or that would interfere with participation (e.g., schizophrenia, borderline personality disorder)
  • Current or recent substance abuse/dependence.
  • Stage IV cancer diagnosis.
  • A cancer recurrence actively requiring treatment.
  • Self-reported active mindfulness practice.
  • Prior participation in a formal mindfulness program (e.g., MBCT, Mindfulness-Based Stress Reduction Program, Mindfulness-Based Cancer Recovery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Case Comprehensive Cancer Center, Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

MeSH Terms

Conditions

DepressionNeoplasmsBreast NeoplasmsProstatic NeoplasmsColorectal Neoplasms

Interventions

Stress Mindset Measure

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorNeoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Chelsea Siwik, PhD

    Case Comprehensive Cancer Center, Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Narissa McCarty, MS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 31, 2025

First Posted

February 6, 2025

Study Start (Estimated)

August 3, 2026

Primary Completion (Estimated)

March 31, 2028

Study Completion (Estimated)

March 31, 2029

Last Updated

January 23, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

After the completion of the study and the associated publication, we will deposit de-identified data and metadata (i.e., codebook, focus group interview guides, protocols) that are necessary for or of sufficient quality to validate and replicate the research findings in the Open Science Framework repository (https://osf.io/).

Shared Documents
STUDY PROTOCOL
Time Frame
Data will become available after the completion of the study and the associated publication and will remain available indefinitely.

Locations